Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. (Q39858360)

From Wikidata

Jump to navigation Jump to search

scientific article published on 8 June 2010

Language	Label	Description	Also known as
English	Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.	scientific article published on 8 June 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20621711%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20621711%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

0 references

secondary progressive multiple sclerosis

0 references

multiple sclerosis

0 references

1 reference

based on heuristic

inferred from title

author name string

Raju Kapoor

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20621711%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Julian Furby

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20621711%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Thomas Hayton

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20621711%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Daniel R Altmann

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20621711%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Robert Brenner

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20621711%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Jeremy Chataway

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20621711%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Richard A C Hughes

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20621711%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

publication date

8 June 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20621711%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Lancet Neurology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20621711%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20621711%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20621711%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

681-688

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20621711%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

General mechanisms of axonal damage and its prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Nitric oxide toxicity in CNS white matter: an in vitro study using rat optic nerve

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Axonal protection using flecainide in experimental autoimmune encephalomyelitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Axonal protection achieved in a model of multiple sclerosis using lamotrigine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Progressive cerebral atrophy in multiple sclerosis. A serial MRI study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Multimodal image coregistration and partitioning--a unified framework

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Spinal cord atrophy and disability in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A study validating changes in the multiple sclerosis functional composite

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Cortical demyelination and diffuse white matter injury in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Gray matter atrophy in multiple sclerosis: a longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Sodium channel expression within chronic multiple sclerosis plaques

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamotrigine in trigeminal neuralgia secondary to multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The search for responsive clinical endpoints in primary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Sodium channels contribute to microglia/macrophage activation and function in EAE and MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Imaging outcomes for neuroprotection and repair in multiple sclerosis trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970131-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(10)70131-9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20621711%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20621711%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39858360&oldid=2091623620"